Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 15/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336721 | 1.00 | S1PR3 (0.53) | S1PR3MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL336720 | 1.00 | S1PR3 (0.53) | S1PR3MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL337112 | 0.88 | S1PR3 (0.57) | S1PR3MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL802961 | 0.88 | S1PR3 (0.57) | S1PR3MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL8233577 | 0.87 | S1PR3 (0.49) | S1PR3MAPTALDH1A1 | |
| SCHEMBL337115 | 0.82 | S1PR3 (0.61) | S1PR3ALDH1A1KDM4E | |
| SCHEMBL337180 | 0.81 | S1PR3 (0.60) | S1PR3LMNASMN1; SMN2 | |
| SCHEMBL337046 | 0.78 | S1PR3 (0.65) | S1PR3MAPTALDH1A1 | |
| SCHEMBL337334 | 0.77 | S1PR3 (0.56) | S1PR3 | |
| SCHEMBL336895 | 0.72 | LMNA (0.54) | S1PR3MAPTALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | DONELLO JOHN E | 2011-01-13 | — | — | US | disclosed |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | DONELLO JOHN E | 2011-01-13 | — | — | US | disclosed |
| WO-2010129553-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING CONDITIONS OF THE EYE | ALLERGAN, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100249069-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | DONELLO JOHN E | 2010-09-30 | — | — | US | disclosed |
| US-20100249069-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | DONELLO JOHN E | 2010-09-30 | — | — | US | disclosed |
| WO-2008141013-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885MAPT 3312/4885ALDH1A1 3604/4885 |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885MAPT 4413/4885ALDH1A1 2262/4885 |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885MAPT 2739/4885ALDH1A1 3863/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885MAPT 3541/4885ALDH1A1 3166/4885 |
| US-20100249069-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885MAPT 3312/4885ALDH1A1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.